33 results on '"Kubota, Ryuji"'
Search Results
2. Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor
3. Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor
4. A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
5. HTLV-1-associated myelopathy/tropical spastic paraplegia with sporadic late-onset nemaline myopathy: a case report
6. Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
7. The ridge line of left pulmonary vein isolation from left atrial appendage can subsequently increase the completion rate of the mitral isthmus block line
8. Population pharmacokinetics of duloxetine in Japanese pediatric patients with major depressive disorder
9. Development of a SARS‐CoV‐2 viral dynamic model for patients with COVID‐19 based on the amount of viral RNA and viral titer
10. Comparison of the empirical linear ablation and low voltage area-guided ablation in addition to pulmonary vein isolation in patients with persistent atrial fibrillation: a propensity score-matched analysis
11. Geographic characteristics of HTLV-1 molecular subgroups and genetic substitutions in East Asia: Insights from complete genome sequencing of HTLV-1 strains isolated in Taiwan and Japan
12. Iliopsoas muscle weakness as a key diagnostic marker in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
13. Efficacy of L-arginine in patients with HTLV-1-associated neurological disease
14. Identification and tracking of pathological T cell clones in virus-associated neurologic disease
15. 530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
16. Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations
17. VISUAL EVALUATION OF CORONARY CT IMAGES USING LATEST MOTION ARTIFACT CORRECTION TECHNIQUE
18. Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial
19. Evaluation of drug‐drug interactions of ensitrelvir, a SARS‐CoV‐2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical study
20. Identification and tracking of HTLV-1–infected T cell clones in virus-associated neurologic disease
21. Anti-ganglionic acetylcholine receptor antibodies in functional neurological symptom disorder/conversion disorder
22. Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
23. Efficacy of l ‐Arginine treatment in patients with HTLV‐1‐associated neurological disease
24. 1131. Evaluation of drug-drug interaction potential of ensitrelvir for CYP3A by clinical studies and physiologically-based pharmacokinetic model
25. 1136. No Change of Pharmacokinetics of Metformin by Concomitant Use of Ensitrelvir
26. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
27. Seroprevalence of anti-ganglionic acetylcholine receptor antibodies in patients with functional neurological symptom disorder/conversion disorder
28. The ridge line of left pulmonary vein isolation from left atrial appendage can subsequently increase the completion rate of the mitral isthmus block line
29. Iliopsoas Muscle Weakness as a Key Diagnostic Marker in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
30. Additional file 1 of Comparison of the empirical linear ablation and low voltage area-guided ablation in addition to pulmonary vein isolation in patients with persistent atrial fibrillation: a propensity score-matched analysis
31. Efficacy of l‐Arginine treatment in patients with HTLV‐1‐associated neurological disease.
32. High Prevalence of HTLV-1 Carriers Among the Elderly Population in Kagoshima, a Highly Endemic Area in Japan
33. HLA-A*24 Increases the Risk of HTLV-1-Associated Myelopathy despite Reducing HTLV-1 Proviral Load.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.